JAK2 Mutations are present in all cases of polycythemia vera (original) (raw)

Leukemia volume 22, page 1289 (2008)Cite this article

The JAK2 V617F point mutation has been described in 65–97% of patients with polycythemia vera (PV).1 Previously, 17 phenotypical cases of PV from a large group of patients from three institutions were initially reported as JAK2 V617F negative.2 These cases were reanalyzed in detail to determine the cause, if any, of the JAK2 V617F negativity. Reasons for this initial negativity included inaccurate clinical diagnosis, relatively insensitive laboratory techniques, insufficient material for retesting, and possible treatment effect. It was predicted that when tested appropriately, JAK2 mutations would be found in all new cases of PV.2

To address the assay sensitivity issue, we studied a total of 105 PV cases diagnosed by Polycythemia Vera Study Group criteria using three different assays of distinct analytical sensitivity. We defined the sensitivity by mixing DNA from JAK2 _V617F_-containing human erythroid leukemia cells (HEL) with that from normal peripheral blood mononuclear cells, so that 1% sensitivity would detect one part of HEL DNA in 100 parts of normal DNA. The first method used was pyrosequencing, which involves synthetic nucleotide extension by DNA polymerase. The method reliably detects JAK2 V617F when the mutant allele is greater than 5%.1 The second method was a standard amplification refractory mutation system (ARMS) PCR assay , which detects the mutant allele when it occupies more than 1% of total DNA.3 The third method was a modified highly sensitive ARMS assay.4 The analytic sensitivity of the modified ARMS assay reaches 0.1% and has a false positive rate of less than 0.01% (we found 1 positive case in 300 individuals without myeloid disorders).5 Of 105 PV cases, the combination of all three assays detected the JAK2 V617F allele in 104. In the remaining case, the JAK2 exon 12 deletion (E543–D544 del) was detected. Therefore, mutations in JAK2 have been detected in 100% of 105 PV patients examined.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
    Article CAS Google Scholar
  2. Verstovsek S, Silver RT, Cross NCP, Tefferi A . JAK2 V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006; 20: 2067.
    Article CAS Google Scholar
  3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
    Article CAS Google Scholar
  4. Chen Q, Lu P, Jones AV, Cross NCP, Silver RT, Wang YL . Amplification refractory mutation system (ARMS), a highly sensitive and simple PCR assay for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007; 9: 272–276.
    Article CAS Google Scholar
  5. Wang YL, Lee JW, Kui JS, Chadburn A, Cross NCP, Knowles DM et al. Evaluation of JAK2 V617F in B- and T-cell neoplasms: identification of JAK2 V617F mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematologica 2007; 118: 209–214.
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Molecular Hematopathology Laboratory, Weill Medical College of Cornell University, New York, NY, USA
    Y L Wang
  2. Division of Hematology–Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    K Vandris, F Adriano & R T Silver
  3. Wessex Regional Genetics Laboratory, Salisbury District Hospital, University of Southampton, Salisbury, Wiltshire, UK
    A Jones & N C P Cross
  4. Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University, New York, NY, USA
    P Christos

Authors

  1. Y L Wang
    You can also search for this author inPubMed Google Scholar
  2. K Vandris
    You can also search for this author inPubMed Google Scholar
  3. A Jones
    You can also search for this author inPubMed Google Scholar
  4. N C P Cross
    You can also search for this author inPubMed Google Scholar
  5. P Christos
    You can also search for this author inPubMed Google Scholar
  6. F Adriano
    You can also search for this author inPubMed Google Scholar
  7. R T Silver
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toY L Wang or R T Silver.

Rights and permissions

About this article

Cite this article

Wang, Y., Vandris, K., Jones, A. et al. JAK2 Mutations are present in all cases of polycythemia vera.Leukemia 22, 1289 (2008). https://doi.org/10.1038/sj.leu.2405047

Download citation

This article is cited by